 CAMBRIDGE, Mass. and NEW YORK, Aug. 10, 2021 GLOBE NEWSWIRE -- Black Diamond Therapeutics, Inc. Nasdaq: BDTX, a precision oncology medicine company pioneering the discovery and development of small molecule, MasterKey therapies, today announced the appointment of Mark A. Velleca, M.D., Ph.D. to its Board of Directors. Dr. Velleca brings over 20 years of leadership experience in the biotechnology industry, particularly in the field of oncology, most recently serving as Chief Executive Officer of G1 Therapeutics. 